Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV

Cell Reports Methods(2022)10.1016/j.crmeth.2022.100236Source: DataRank Database

Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV is a research paper published in Cell Reports Methods (2022). On theSindex it has a DataRank of 0. It has been cited 57 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access57 citations

Download PDF

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 3.95)OA: goldTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Shibi Likhite ORCID,Ezgi Elmas ORCID,Kenta Yamamoto ORCID,M. Schwartz ORCID,Kinnari Sorathia ORCID

Live enrichment

PubMed:35784645 PMC:PMC9243630 OpenAlex:https://openalex.org/W4282553073

NCI

Grant: U54-CA232561

Kiadis Pharma

Grant: PCT-US2018/020187

Kiadis Pharma

Grant: PCT-US2019/032,670

Kiadis Pharma

Grant: PCT-US2020/018,384

Kiadis Pharma

Grant: PCT-US2020/025,454

Kiadis Pharma

Grant: PCT-US2020/02545

Kiadis Pharma

Grant: US62/805,394

Kiadis Pharma

Grant: US62/815,625

Kiadis Pharma

Grant: US62/900,245

Kiadis Pharma

Grant: US62/928,524

Kiadis Pharma

Grant: US62/987,935

Kiadis Pharma

Grant: US63/018,108

Kiadis Pharma

Grant: US63/105,722

Kiadis Pharma

Grant: WO2019/222,503-A1

NCI NIH HHS

Grant: U54 CA232561

CancerFree KIDS

Hyundai Hope on Wheels

National Cancer Institute

National Institutes of Health

FWCI

3.95

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S2667237522001059/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2667237522001059/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2667237522001059?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2667237522001059?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.crmeth.2022.100236

Fields of Study

CRISPR and Genetic EngineeringCAR-T cell therapy researchImmune Cell Function and InteractionHumansKiller Cells, NaturalGene EditingImmunotherapy

MeSH Terms

Gene EditingHumansImmunotherapyKiller Cells, Natural

Keywords

Transduction (biophysics)TransgeneBiologyGeneCRISPRGene deliveryGenetic enhancementCell biologyCancer researchComputational biologyGeneticsAMlNatural killer cellAcute myeloid leukemiaNKCarChimeric Antigen ReceptorGene EditingHdrClustered Regularly Interspaced Short Palindromic RepeatsAdeno-associated Virus 6Homology Directed RepairAav6CrispaintCas9/RibonucleoproteinCas9/RnpCd33car-Nk

Sustainable Development Goals

SDG 0: Good health and well-being